HJC-0350

Cas No.:	885434-70-8
Chemical Name:	2,4-Dimethyl-1-(2,4,6-trimethyl-benzenesulfonyl)-1H-pyrrole
Synonyms:	HJC 0350;2,4-dimethyl-1-(2,4,6-trimethyl-benzenesulfonyl)-1H-pyrrole;Hjc-0350;2,4-Dimethyl-1-[(2,4,6-trimethylphenyl)sulfonyl]-1H-pyrrole;HJC0350;2,4-dimethyl-1-(2,4,6-trimethylphenyl)sulfonylpyrrole;1-(mesitylsulfonyl)-2,4-dimethyl-1H-pyrrole;AMBZ0342;GTPL6556;SYN5084;AOB3682;AFZWZVLPIMHLSE-UHFFFAOYSA-N;HMS3744E19;HMS3653N09;BCP28371;BDBM50425531;s7500;AM85945;AK676066
SMILES:	S(C1C(C([H])([H])[H])=C([H])C(C([H])([H])[H])=C([H])C=1C([H])([H])[H])(N1C([H])=C(C([H])([H])[H])C([H])=C1C([H])([H])[H])(=O)=O
Formula:	C15H19NO2S
M.Wt:	277.3819
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	HJC0350 is a potent and specific EPAC2 antagonist with an IC50 of 0.3 µM.
In Vitro:	HJC0350 has an apparent IC50 value of 0.3 µM for competing with 8-NBD-cAMP binding of EPAC2, and is about 133-fold more potent than cAMP. HJC0350 is found not to inhibit EPAC1-mediated Rap1-GDP exchange activity at 25 µM in the presence of equal concentration of cAMP, indicating that it is EPAC2-specific antagonists. Pretreatment of HEK293/EPAC2-FL cells with 10 µM HJC0350 fully blocks the 007-AM induced decrease of FRET[1].
References:	[1]. Chen H, et al. Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem. 2013 Feb 14;56(3):952-62.